Table I.
Leptin and Ob-R expression in human cancer tissues by immunohistochemical staining
| Tissue | Subtype | Leptin | Ob-R | References |
|---|---|---|---|---|
| B-cell | Lymphoma | ND | 39.8% | [177] |
| Bladder | Carcinoma | ND | ↓↓ | [51] |
| Brain | Glioma | 55.2% | 80.5% | [56] |
| Breast | Carcinoma | 92% | 83% | [52] |
| Colon | Carcinoma | 73.5% | 72.5% | [255–256] |
| Endometrioid | Adenocarcinomas | 60% | 31% | [257] |
| Esophagus | Carcinoma | ND | 91% | [57] |
| Kidney | Carcinoma | ↑↑ | 38.6% | [258] |
| Liver | Carcinnoma | 60.3% | 53% | [259–260] |
| Lung | Adenocarcinoma | 69.0% | ND | [261] |
| Ovary | Carcinoma | 89.5% | 59.2% | [53] |
| Prostate | Cancer | 96.7% | 63.3% | [54] |
| Skin | Melanoma | 90.9% | 43.8% | [55] |
| Thyroid | Carcinoma | ND | 80% | [59] |
| Thyroid | Carcinoma | 37% | 51%, | [58] |
ND: Not determined; ↑↑, High serum leptin in cancer patients; ↓↓, low Ob-R expression